Navamedic granted Norway import licence
Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced that the Company has been granted import licence for medicinal products by the Norwegian Medicines Agency.
The licence enables Navamedic to import its coming flow of pharmaceutical products to the Norwegian market and accumulate inventory with an approved wholesaler in Norway.
Navamedic is currently preparing the launches of several generic drugs on the Nordic and Benelux markets, based on its partnership with Aspen Pharmaceuticals, one of the world's largest manufacturers of generic pharmaceutical products.
For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.
Navamedic ASA is a Norwegian pharmaceutical products company. Through its subsidiary Vitaflo Scandinavia the Company is a distributor of a broad range of nutrition and pharmaceutical products in the Nordic markets. Navamedic is currently building up a generic pharmaceutical business for the Nordic, Dutch and Belgian markets based on its partnership with Aspen Healthcare of South Africa. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.